by Truveta Research | Dec 16, 2024 | Research, Research Insights
In partnership with Reuters, Truveta Research explored the percentage of patients who received a first-time diagnosis of type 2 diabetes, cardiovascular disease, or sleep apnea within 15 days of their first-time GLP-1 prescriptions. Truveta Research found that for...
by Truveta Research | Dec 14, 2024 | Research, Research Insights
First-time amphetamine/dextroamphetamine prescription rates remained stable overall, but increased significantly for people 30-44, 45-64, and 65+ years of age. The percentage of prescriptions filled within 5 days of being written reached their lowest values in March...
by Truveta Research | Dec 11, 2024 | Research, Research Insights
The rate of first-time ADHD diagnoses has increased since 2021. The largest increases in first-time ADHD diagnosis rates were seen in the 30-44-year-old and 45-64-year-old age groups. Age groups under 30 years old did not see increases in first-time ADHD diagnosis...
by Truveta staff | Dec 10, 2024 | Research
“For the first time in the history of health, we have enough data at scale to dramatically advance innovation in healthcare” – Michael Slubowski, president & CEO, Trinity Health Electronic health record (EHR) data is rapidly changing how life sciences,...
by Truveta staff | Nov 25, 2024 | Research
RSV-associated hospitalizations increased 191.5% throughout October 2024. RSV-associated hospitalizations also increased in vulnerable populations with a 233.3% in infants and young children (aged 0-4) and 137.0% increase in older adults (65+); 2.4% of all...
by Truveta staff | Nov 7, 2024 | Research
GLP-1 medications are revolutionizing the way we treat type 2 diabetes and obesity. First discovered forty years ago, GLP-1 receptor agonists were initially approved for type 2 diabetes in 2005, with the first weight-loss-specific approval following in 2014. Flash...
